Company intelligence / Profile preview

Shepherd Pharma

Boston, Massachusetts, United Statesissuu.com ↗

Ownership: Private
Employees: ~16
Development stage: Other

Overview

Shepherd Therapeutics uses its proprietary DELVE precision-oncology platform to identify mechanisms of drug response/resistance in rare cancers. The company partners with foundations and biotechs to develop treatments for over a hundred rare cancer types. Its pipeline includes both internal programs and partnered assets such as volasertib for rhabdomyosarcoma. Clinical results are not yet widely published; most programs are preclinical or early clinical.

Therapeutic areas: Oncology
Modalities: Small moleculeMonoclonal antibodyPlatform/agnostic approach
Industry: Biotech

Partnerships

Oncoheroes Biosciences—collaboration using DELVE platform for pediatric/rare adult oncology therapeutics including volasertib development.

Beyond the preview

Go deeper on Shepherd Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shepherd Pharma.

Explore the full profile